<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646020</url>
  </required_header>
  <id_info>
    <org_study_id>TAPE001</org_study_id>
    <nct_id>NCT02646020</nct_id>
  </id_info>
  <brief_title>Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment</brief_title>
  <acronym>EGFR-TKIs</acronym>
  <official_title>Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis is that aprepitant is more effective than desloratadine in relieving
      pruritus caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective
      treatment defined as visual analogue scale (VAS) decrease ≥ 50% after treatment compared to
      baseline score. 130 NSCLC patients undertaken EGFR-TKI and suffer from moderate or severe
      pruritus (VAS score ≥ 4) will be enrolled in this study, and stratified (gender, first or
      seconde generation TKIs, VAS 4-6 or 7-10) randomized (1:1) into aprepitant or desloratadine
      treatment. VAS investigation will be taken once a week to treatment end or follow-up end (≤12
      weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized control, double-blinded, phase II clinical trial. Study
      hypothesis is that aprepitant is more effective than desloratadine in relieving pruritus
      caused by EGFR TKIs. Primary endpoint is the effective rate of pruritus, effective treatment
      defined as visual analogue scale (VAS) decrease ≥ 50% after treatment compared to baseline
      score. Secondary endpoints are the duration of pruritus relieving, defined as the time from
      pruritus effective relief to VAS score increase ≥ baseline level, the VAS inquiry will be
      taken once a week, treatment last for 28 days unless pruritus recurrence or discontinuation
      of EGFR-TKI. Quality of life investigation will be performed at baseline, treatment end and
      follow-up end using SKINDEX-16 questionnaire. 130 NSCLC patients undertaken EGFR-TKI and
      suffer from moderate or severe pruritus (VAS score ≥ 4) will be enrolled in this study, and
      stratified (gender, first or seconde generation TKIs, VAS 4-6 or 7-10) randomized (1:1) into
      aprepitant or desloratadine treatment. Aprepitant arm will be administrated aprepitant 125mg
      d1, 80mg d3 and d5, along with placebo 5mg d1-d28; desloratadine arm will be administrated
      placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28. Tolerance evaluation
      will be taken according to National Cancer Institute (NCI)-Common Terminology Criteria (CTC)
      For Adverse Events (AE) V4.03. Treatment end in d28, VAS investigation will be taken once a
      week to treatment end, if the treatment is not effective, patients will be unblinded and
      receive other treatment decided by investigator. If the treatment is effective, follow-up
      will be taken up to 12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effective rate of pruritus relieving</measure>
    <time_frame>day 28 at the treatment ends</time_frame>
    <description>effective treatment of pruritus relieving defined as visual analogue scale (VAS) decrease ≥ 50% after treatment compared to baseline score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of pruritus relieving</measure>
    <time_frame>12 weeks at the follow-up end</time_frame>
    <description>the time from pruritus effective relief to VAS score increase ≥ baseline level, the VAS inquiry will be taken once a week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline quality of life assessment at treatment ends</measure>
    <time_frame>baseline, 28 days at the treatment ends</time_frame>
    <description>using SKINDEX-16 questionnaire to assess patients quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Aprepitant and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desloratadine and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant and placebo</intervention_name>
    <description>aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)</description>
    <arm_group_label>Aprepitant and placebo</arm_group_label>
    <other_name>Treatment arm: Aprepitant and placebo administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine and placebo</intervention_name>
    <description>placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)</description>
    <arm_group_label>desloratadine and placebo</arm_group_label>
    <other_name>Comparative arm: desloratadine and placebo administration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or metastatic non small cell lung cancer

          -  Harboured with positive EGFR mutation (19del, 21L858R, 21861Q, etc)

          -  Undertaken EGFR TKIs treatment (gefitinib, erlotinib, icotinib, afatinib, etc)

               -  18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0-2

          -  Moderate or severe pruritus (VAS score ≥ 4) first occur after EGFR TKIs treatment

          -  Life expectancy ≥ 3 months

          -  Orally drug administration with no difficulty

          -  pregnancy test negative in 7 days for women of child-bearing age; willing to take
             contraception measures.

          -  Signed informed consent form (ICF)

        Exclusion Criteria:

          -  Systemically treatment with Neurokinin-1 (NK-1) receptor inhibitors, antihistamines
             drugs, antibiotics, cortical hormone therapy, antiepileptic drugs, immunosuppressive
             agents or other drugs might affect treatment in 4 weeks; or locally used of these drug
             in 2 weeks.

          -  Existing skin lesions not EGFR TKIs related, such as skin infection, chronic
             dermatitis, Systemic Lupus Erythematosus (SLE), lymphoma or other diseases.

          -  Total bilirubin ≥ 1.5 Upper Limit Of Normal (ULN)

          -  Serum creatinine ≥mg/dl

          -  AST or ALT ≥ 2.5 ULN without liver metastasis; or ≥ 5 ULN with liver metastasis.

          -  Residual toxicity event ≥ CTC-AE grade 2, except peripheral neurotoxicities.

          -  Central nervous system (CNS) metastasis or spinal compression; except no symptoms and
             with no cortical hormonotherapy in 4 weeks.

          -  Clinical evidence of interstitial lung disease

          -  Any severe or uncontrolled systemic diseases judged by investigators.

          -  Any contraindication of Neurokinin-1 receptor inhibitors and desloratadine.

        Discontinuation Criteria

          -  Invalid subject after randomization

          -  Major protocol violations judged by investigators.

          -  Poor compliance

          -  Intolerable adverse events

          -  Subject withdraw ICF

          -  Any pregnancy events

          -  No clinical benefits due to clinical adverse events, laboratory abnormalities or other
             medical conditions

          -  Other reasons of treatment discontinuation judged by investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center of Sun-Yat Sen University (CCSYSU)</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.</citation>
    <PMID>19692680</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.</citation>
    <PMID>21783417</PMID>
  </results_reference>
  <results_reference>
    <citation>Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.</citation>
    <PMID>16014882</PMID>
  </results_reference>
  <results_reference>
    <citation>Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.</citation>
    <PMID>20493771</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17.</citation>
    <PMID>22512843</PMID>
  </results_reference>
  <results_reference>
    <citation>Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007 May;12(5):610-21. Review.</citation>
    <PMID>17522250</PMID>
  </results_reference>
  <results_reference>
    <citation>Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1. Review.</citation>
    <PMID>21630130</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer. 2011 Oct;19(10):1667-74. doi: 10.1007/s00520-010-0999-2. Epub 2010 Sep 5.</citation>
    <PMID>20820812</PMID>
  </results_reference>
  <results_reference>
    <citation>Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010 Apr;24(4):453-9. doi: 10.1111/j.1468-3083.2009.03446.x. Epub 2009 Sep 27.</citation>
    <PMID>19793151</PMID>
  </results_reference>
  <results_reference>
    <citation>Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007 Dec 1;25(34):5390-6.</citation>
    <PMID>18048820</PMID>
  </results_reference>
  <results_reference>
    <citation>Porzio G, Aielli F, Verna L, Porto C, Tudini M, Cannita K, Ficorella C. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage. 2006 Nov;32(5):397-8.</citation>
    <PMID>17085262</PMID>
  </results_reference>
  <results_reference>
    <citation>Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010 Jun 4;5(6):e10968. doi: 10.1371/journal.pone.0010968.</citation>
    <PMID>20532044</PMID>
  </results_reference>
  <results_reference>
    <citation>Ständer S, Weisshaar E. Medical treatment of pruritus. Expert Opin Emerg Drugs. 2012 Sep;17(3):335-45. doi: 10.1517/14728214.2012.711316. Epub 2012 Aug 7. Review.</citation>
    <PMID>22870909</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007 Jun;156(6):1272-7.</citation>
    <PMID>17535226</PMID>
  </results_reference>
  <results_reference>
    <citation>Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets. 2006 Aug;7(8):975-92. Review.</citation>
    <PMID>16918326</PMID>
  </results_reference>
  <results_reference>
    <citation>Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011 Mar;164(3):665-7. doi: 10.1111/j.1365-2133.2010.10108.x. Epub 2011 Jan 28.</citation>
    <PMID>21039410</PMID>
  </results_reference>
  <results_reference>
    <citation>Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer. 2010 Sep;18(9):1229-30. doi: 10.1007/s00520-010-0895-9. Epub 2010 Jun 11.</citation>
    <PMID>20544226</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiménez Gallo D, Albarrán Planelles C, Linares Barrios M, Fernández Anguita MJ, Márquez Enríquez J, Rodríguez Mateos ME. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant. Dermatol Ther. 2014 May-Jun;27(3):178-82. doi: 10.1111/dth.12113. Epub 2013 Dec 2.</citation>
    <PMID>24517320</PMID>
  </results_reference>
  <results_reference>
    <citation>Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.</citation>
    <PMID>22995650</PMID>
  </results_reference>
  <results_reference>
    <citation>Marquez D, Ramonda C, Lauxmann JE, Romero CA, Vukelic VL, Martinatto C, Barrón B, Novoa PA, Peixoto AJ, Orías M. Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin. J Bras Nefrol. 2012 Jun;34(2):148-52.</citation>
    <PMID>22850916</PMID>
  </results_reference>
  <results_reference>
    <citation>Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30(2):109-22. doi: 10.2165/11530930-000000000-00000. Review.</citation>
    <PMID>20067329</PMID>
  </results_reference>
  <results_reference>
    <citation>Grob JJ, Auquier P, Dreyfus I, Ortonne JP. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol. 2008 Jan;22(1):87-93. doi: 10.1111/j.1468-3083.2007.02385.x.</citation>
    <PMID>18181978</PMID>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol. 2007;8(1):37-42.</citation>
    <PMID>17298105</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>January 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 2, 2016</last_update_submitted>
  <last_update_submitted_qc>January 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>M.D. Professor</investigator_title>
  </responsible_party>
  <keyword>pruritus</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Receptor, Epidermal Growth Factor</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

